Background: Management of patients with a very high prostate-specific antigen (PSA) level (≥98.0 ng/mL) but clinically localized (N0M0) prostate cancer is challenging. This study sought to determine practice patterns and outcomes among these patients. Patients and Methods: A total of 748,825 patients with prostate cancer from 2004 through 2012 were identified using the National Cancer Database. These patients were subdivided by PSA level (0–9.9, 10.0–19.9, 20.0–39.9, 40.0–59.9, 60.0–79.9, 80.0–97.9, and ≥98.0 ng/mL), nodal status (N0 vs N1), and distant metastases (M0 vs M1). Rates of locoregional treatment and 5-year overall survival (OS) in each group were determined. Survival was compared using Cox regression after adjusting for multiple patient-specific factors. Results: The rate of locoregional treatment for patients with N0M0 disease and PSA level ≥98.0 ng/mL was significantly lower than for those with N1M0 disease (52.6% vs 60.4%; P<.001) or N0M0 disease and PSA level <98.0 ng/mL (52.6% vs 86.6%; P<.001). The 5-year OS rate was similar for patients with N1M0 disease and those with N0M0 disease and a very high PSA level (63.2% vs 59.1%; adjusted hazard ratio [aHR], 0.91; P=.063). The survival benefit associated with locoregional treatment was higher among those with N0M0 disease and a very high PSA level than among those with N1M0 disease (aHR, 0.28 vs 0.44; P<.001). Conclusions: Patients with clinical N0M0 disease and a very high PSA level (≥98.0 ng/mL) have outcomes similar to those with N1 disease but receive locoregional treatment at a lower rate. Future work is needed to investigate the utility of locoregional treatment in this population.
Submitted November 9, 2018; accepted for publication February 8, 2019.Author contributions:Study concept and design: Muralidhar, Nguyen, King, Orio. Data acquisition, analysis, and interpretation: All authors. Statistical analysis: Muralidhar, Nguyen, King, Orio. Drafting of manuscript: All authors. Critical revision of the manuscript for important intellectual content: All authors.Disclosures: Dr. Nguyen has disclosed that he receives support from Bayer, Astellas, Ferring, Dendreon, Blue Earth, Genome Dx, Augmenix, Boston Scientific, and Janssen. Dr. Efstathiou has disclosed that he is a scientific advisor for Janssen and Blue Earth Diagnostics. The remaining authors have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.Correspondence: Peter F. Orio III, DO, MS, Department of Radiation Oncology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115. Email: Peter_Orio@dfci.harvard.edu
Mohler JL, Lee RJ, Antonarakis ES, . NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2018. To view the most recent version, visit NCCN.org. Accessed October 1, 2018.
Pilepich MV, Winter K, Lawton CA, . Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285–1290.
WidmarkA, KleppO, SolbergA, . Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301–308.10.1016/S0140-6736(08)61815-219091394)| false
BilimoriaKY, StewartAK, WinchesterDP, . The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683–690.10.1245/s10434-007-9747-318183467)| false
Briganti A, Karnes RJ, Da Pozzo LF, . Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol 2011;59:832–840.
BrigantiA, KarnesRJ, Da PozzoLF, . Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol 2011;59:832–840.10.1016/j.eururo.2011.02.02421354694)| false
RusthovenCG, CarlsonJA, WaxweilerTV, . The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys 2014;88:1064–1073.10.1016/j.ijrobp.2014.01.00824661660)| false
Akin-Akintayo OO, Jani AB, Odewole O, . Change in salvage radiotherapy management based on guidance with FACBC (Fluciclovine) PET/CT in postprostatectomy recurrent prostate cancer. Clin Nucl Med 2017;42:e22–28.
Akin-AkintayoOO, JaniAB, OdewoleO, . Change in salvage radiotherapy management based on guidance with FACBC (Fluciclovine) PET/CT in postprostatectomy recurrent prostate cancer. Clin Nucl Med 2017;42:e22–28.10.1097/RLU.000000000000137927749412)| false
Rodrigues G, Bae K, Roach M, . Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys 2011;80:445–452.
RodriguesG, BaeK, RoachM, . Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys 2011;80:445–452.10.1016/j.ijrobp.2010.02.03420615632)| false
TaiP, TonitaJ, WoitasC, . Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen. Int J Radiat Oncol Biol Phys 2012;83:e525–530.2248370110.1016/j.ijrobp.2012.01.041)| false
VanasupaBP, PaquetteEL, WuH, . The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. Urol Oncol 2002;7:167–172.10.1016/S1078-1439(02)00187-412474533)| false
MahalBA, AizerAA, ZiehrDR, . Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology 2014;84:386–392.10.1016/j.urology.2014.05.00924975710)| false
MahalBA, AizerAA, ZiehrDR, . The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis 2014;17:273–279.10.1038/pcan.2014.2324980272)| false
FalchookAD, SalloumRG, HendrixLH, . Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int J Radiat Oncol Biol Phys 2014;89:243–248.2432178410.1016/j.ijrobp.2013.10.023)| false
PrasadSM, GuX, LipsitzSR, . Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer 2012;118:1260–1267.2182311210.1002/cncr.26416)| false